Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
NPJ Precis Oncol
; 5(1): 76, 2021 Aug 12.
Article
de En
| MEDLINE
| ID: mdl-34385567
ABSTRACT
Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
NPJ Precis Oncol
Année:
2021
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique